PIK 3 CA hotspot mutations in circulating tumor cells and paired circulating tumor DNA in breast cancer: a direct comparison study
Liquid biopsy analysis, mainly based on circulating tumor cells ( CTC s) and circulating tumor DNA (ct DNA ), provides an extremely powerful tool for the molecular profiling of cancer patients in real time. In this study, we directly compared PIK 3 CA hotspot mutations (E545K, H1047R) in Ep CAM ‐pos...
Saved in:
Published in | Molecular oncology Vol. 13; no. 12; pp. 2515 - 2530 |
---|---|
Main Authors | , , , , , , , |
Format | Journal Article |
Language | English |
Published |
01.12.2019
|
Online Access | Get full text |
Cover
Loading…
Summary: | Liquid biopsy analysis, mainly based on circulating tumor cells (
CTC
s) and circulating tumor
DNA
(ct
DNA
), provides an extremely powerful tool for the molecular profiling of cancer patients in real time. In this study, we directly compared
PIK
3
CA
hotspot mutations (E545K, H1047R) in Ep
CAM
‐positive
CTC
s and paired plasma‐ct
DNA
in breast cancer (BrCa).
PIK
3
CA
hotspot mutations in
CTC
s and ct
DNA
were analyzed using our previously developed highly sensitive (0.05%), specific, and validated assay in plasma‐ct
DNA
from 77 early and 73 metastatic BrCa patients and 40 healthy donors. We further analyzed and directly compared
PIK
3
CA
hotspot mutations in
DNA
s isolated from CellSearch
®
cartridges (
CTC
s) and paired plasma‐ct
DNA
, in 56 cases of early and 27 cases of metastatic breast cancer, and 16 corresponding primary tumors. In plasma‐ct
DNA
,
PIK
3
CA
hotspot mutations were identified in 30/77(39.0%) early and 35/73(47.9%) metastatic BrCa cases; none (0/40, 0%) of the healthy donors’ plasma‐ct
DNA
samples were positive. Our direct comparison study in
DNA
s isolated from CellSearch
®
cartridges (
CTC
s) and paired plasma‐ct
DNA
from the same blood draws has shown a lack of concordance in early BrCa (27/56, 48.2%), while the concordance in the metastatic setting was higher (18/27, 66.6%). Our results were validated by dd
PCR
methodology, and the concordance between our assay and dd
PCR
for
PIK
3
CA
E545K hotspot mutation was 30/37 (81.1%). In many cases,
PIK
3
CA
hotspot mutations were detected in samples found to be negative for
CTC
s in CellSearch
®
. Our data demonstrated for the first time that (a)
PIK
3
CA
hotspot mutations are present at high frequencies in
CTC
s isolated from CellSearch
®
cartridges and paired plasma‐ct
DNA
both in early and metastatic BrCa, (b) the detection and concordance of
PIK
3
CA
hotspot mutations between plasma‐ct
DNA
and
CTC
s are higher in the metastatic setting, (c)
PIK
3
CA
mutational status significantly changes after therapeutic intervention, and (d)
PIK
3
CA
mutation detection in
CTC
s and plasma‐ct
DNA
provides complementary information. |
---|---|
ISSN: | 1574-7891 1878-0261 |
DOI: | 10.1002/1878-0261.12540 |